StockNote
DP2
Central Pharmaceutical Joint Stock Company 2 (DP2) has the predecessor of Central Pharmaceutical Enterprise 2, was established in 1960. DP2 operates mainly in the field of (i) manufacturing and trading in oriental medicine, traditional medicine, chemical medicinal materials, nutritious food, cosmetics; (ii) trading in medical machinery and equipment. The company officially operates under the model of a joint stock company from March 2005. DP2 is currently managing and operating a GMP - who pharmaceutical factory in Quang Minh Industrial Park, Me Linh, Hanoi with an output of 1,230 million products/year. Some main products of the Company today such as: Aminazin, Sedorazdin, Methionine 250mg, Amoxicillin, Ampicillin, Vitamins of all kinds...
DP2 currently has a market capitalization of roughly VND 98 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 97,4x is 0% above its own 1-year average (97,4x), suggesting the stock is trading richer than its historical norm. P/B stands at 1,6x, 50% above its multi-year average of 1,1x. Return on equity (ROE) is at -24,4%, down from -14,1% the year before. Its debt-to-equity ratio of 0,1x is low, reflecting a conservative capital structure. In 2025, revenue fell 1% year-on-year while after-tax profit fell 95%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.